Beyond their role in patients with diabetes, accumulating evidence shows that GLP-1 RAs also facilitate weight loss in individuals with overweight or obesity who do not have diabetes. Since 2019, semaglutide has been increasingly studied in large-scale randomized controlled trials (RCTs) involving non-diabetic populations, consistently showing significant weight reduction [3]. Here, GCG is linked to Obesity.